Bridge chooses Catalent for opioid addiction treatment manufacture
Catalent completes clinical production of opioid addiction therapeutic developed by Bridge using Zydis technology and gets exclusive license ahead of regulatory filing.
Archives for December 19, 2019
Avid frames Halozyme setback as potential positive for CDMO business
Avid Bioservices sees potential upside to clinical development setback at big customer Halozyme.